Developer docs
API playgroundTry for free, no card

Search company profiles

Peak Proteins

Full company profile

uuid000xqgp

Namestring
Peak Proteins
Legal namestring
Sygnature Discovery Limited
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Peak Proteins was a UK-based contract research organization founded in 2015 in Macclesfield by former AstraZeneca protein biochemistry and structural biology scientists. The company provided specialist protein science and structural biology services supporting drug discovery programs, covering protein expression and purification, membrane proteins, antibodies and biotherapeutics, X-ray crystallography, cryo-EM, macromolecular NMR, and protein characterization including mass spectrometry and FIDA. Its customer base comprised biotech and pharmaceutical sponsors requiring high-quality protein reagents and structural insight for hit identification, hit-to-lead, and lead optimization work.

Peak Proteins no longer operates as an independent entity. It has been fully integrated with Sygnature Discovery, together with NuChem Sciences and SB Drug Discovery, under the unified Sygnature Discovery Limited brand. The combined organization operates from the UK (Nottingham) and Canada (Montréal) and employs over 700 scientists delivering integrated drug discovery from target identification through lead optimization, complemented by scientific solutions in computer-aided drug design, protein and structure sciences, bioscience, chemistry, DMPK, in vivo pharmacology, and form and formulation across multiple modalities and therapeutic areas.

As a contract research organization, the business model is fee-for-service based on custom drug discovery programs and integrated engagements. Pricing is not publicly disclosed and customer concentration data is not available. The combined entity claims to have contributed to multiple clinical candidates and FDA-approved therapies, with founder Dr Simon Hirst leading Sygnature Discovery as CEO.

Short descriptiontext

Peak Proteins was a UK-based contract research organization founded in 2015 by ex-AstraZeneca scientists, providing protein science and structural biology services to drug discovery clients. It has since fully integrated with Sygnature Discovery, NuChem Sciences, and SB Drug Discovery under a single brand.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
protein expression services, structural biology CRO, drug discovery services, X-ray crystallography, cryo-EM analysis
Industry3 codes
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (Drug Discovery & Protein Science Services)
Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Peak Proteins provides protein science and structural biology research services to pharmaceutical and biotechnology clients, including protein expression and purification, membrane protein production, antibody and biotherapeutic engineering, X-ray crystallography, cryo-EM, macromolecular NMR, protein mass spectrometry, and FIDA-based biophysical characterization. Now fully integrated into Sygnature Discovery, these capabilities are delivered alongside integrated drug discovery programs spanning target identification, hit identification, hit-to-lead, and lead optimization.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Peak Proteins operates as part of Sygnature Discovery, a unified contract research organization (CRO) providing integrated drug discovery services. The integrated offering combines multiple service pillars—including Integrated Drug Discovery programs, Computer Aided Drug Design, Protein & Structure sciences, Bioscience, Chemistry, Drug Metabolism and Pharmacokinetics (DMPK), in vivo Pharmacology, and Form & Formulation—delivered by 700+ scientists across Europe and North America. Peak Proteins, along with NuChem Sciences and SB Drug Discovery, has been fully unified under the Sygnature Discovery brand, offering end-to-end drug discovery solutions without competing internal programs.

Product and service13 records
1Target Identification and Validation
CategoryIntegrated Drug Discovery Services
Description

Service delivering robust target identification and validation using an integrated AI-enabled and lab-validated platform, intended for pharmaceutical and biotechnology discovery teams needing early-stage target de-risking.

2Hit Identification
CategoryIntegrated Drug Discovery Services
Description

Service that delivers validated, high-quality hits via integrated technologies and expert collaboration, for pharmaceutical and biotechnology discovery teams progressing targets into hit-to-lead workflows.

3Hit-to-Lead
CategoryIntegrated Drug Discovery Services
Description

Service that progresses high-quality hits through de-risking and profiling with early proof-of-concept work, intended for pharmaceutical and biotechnology discovery teams transitioning toward lead optimisation.

4Lead Optimization
CategoryIntegrated Drug Discovery Services
Description

Service that converts promising leads into clinical candidates using medicinal chemistry, structural biology, and DMPK expertise, for pharmaceutical and biotechnology discovery teams advancing toward IND-enabling studies.

5Protein Expression and Purification
CategoryProtein Science Services
Description

Service producing and purifying recombinant proteins for structural biology, biochemistry, and biotherapeutic discovery, intended for pharmaceutical and biotechnology research teams needing protein reagents.

6Membrane Protein Services
CategoryProtein Science Services
Description

Service that produces and characterises membrane proteins to enable structure-based drug design against challenging integral membrane targets, intended for pharmaceutical and biotechnology discovery teams.

7Antibodies and Biotherapeutics
CategoryBiotherapeutic Discovery Services
Description

Service engineering and characterising antibodies and biotherapeutic proteins for therapeutic development, intended for pharmaceutical and biotechnology teams developing biologic drugs.

8X-Ray Crystallography
CategoryStructural Biology Services
Description

Service providing atomic-resolution X-ray crystal structures of proteins and protein-ligand complexes to support structure-based drug design, intended for pharmaceutical and biotechnology discovery teams.

9Single-Particle Cryo-EM
CategoryStructural Biology Services
Description

Service providing high-resolution cryo-electron microscopy structures of proteins and complexes unsuitable for crystallography, intended for pharmaceutical and biotechnology discovery teams working on challenging targets.

10Macromolecular NMR
CategoryStructural Biology Services
Description

Service delivering solution-state NMR structural and dynamic characterisation of proteins and ligands, intended for pharmaceutical and biotechnology discovery teams requiring complementary structural insights.

11Protein Characterization
CategoryBiophysical Characterization Services
Description

Service providing biophysical and analytical characterisation of proteins, including protein mass spectrometry and FIDA-based analysis, for pharmaceutical and biotechnology teams assessing developability and binding.

12Bioscience Services
CategoryBioscience Services
Description

Service portfolio covering cell line generation, assay development, electrophysiology, high-throughput screening, and cell-based, biochemical, and biophysical assays, intended for pharmaceutical and biotechnology discovery teams.

13Computer Aided Drug Design (CADD)
CategoryComputer-Aided Drug Design Services
Description

Service providing computer-aided drug design spanning bioinformatics, virtual screening, structure-based and ligand-based design, library design, ADMET predictions, and informatics, intended for pharmaceutical and biotechnology discovery teams.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Peak Proteins has fully integrated with Sygnature Discovery, along with NuChem Sciences and SB Drug Discovery, under the unified Sygnature Discovery brand. This integration brings together connected drug discovery capabilities across Europe and North America.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based CRO providing integrated drug discovery services including protein expression, structural biology, medicinal chemistry and DMPK. Highly comparable as a similarly sized UK-headquartered discovery CRO.

TypeDirect peer
Description

Sygnature Discovery is the parent CRO into which Peak Proteins has been fully integrated, offering the same drug discovery, protein science and structural biology services. It is the most directly comparable entity given full operational overlap.

TypeBroad incumbent
Description

Global testing and laboratory services group with significant pharmaceutical and biopharma services exposure. Comparable as a broad incumbent offering protein and analytical services to the biopharma industry.

TypeDirect peer
Description

Specialist structural biology CRO offering protein production, crystallography and structure-based drug design. Comparable as a similarly sized, focused structural biology service provider.

TypeBroad incumbent
Description

Large global drug discovery CRO offering integrated services from target identification through to clinical candidates. Comparable as a broader incumbent in the same integrated discovery services category.

TypeBroad incumbent
Description

Large global CRO/CDMO offering discovery, development and manufacturing services including protein sciences. Comparable as a broad incumbent competing for the same biopharma R&D outsourcing spend.

TypeBroad incumbent
Description

Major global CRO with extensive drug discovery and early development services. Comparable as an incumbent offering overlapping protein science, structural biology and integrated discovery capabilities, though at much larger scale.

TypeEmerging player
Description

AI- and physics-driven drug discovery platform combining computation with structural biology and protein engineering. Comparable as an emerging player intersecting structural biology, protein science and AI-enabled drug design.

TypeDirect peer
Description

Germany-based specialist in protein science and structure-based drug design, including X-ray crystallography and biophysics. Comparable because it serves the same protein science and structure-based discovery niche from a similar size.

TypeEmerging player
Description

Specialist protein science and structural biology CRO now part of WuXi AppTec, focused on protein production, crystallography and biophysics. Comparable as a focused protein science service provider integrated into a broader CRO.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Peak Proteins

Contract Research Organization (Drug Discovery & Protein Science Services)peakproteins.com

Peak Proteins was a UK-based contract research organization founded in 2015 by ex-AstraZeneca scientists, providing protein science and structural biology services to drug discovery clients. It has since fully integrated with Sygnature Discovery, NuChem Sciences, and SB Drug Discovery under a single brand.

What Peak Proteins does

Peak Proteins was a UK-based contract research organization founded in 2015 in Macclesfield by former AstraZeneca protein biochemistry and structural biology scientists. The company provided specialist protein science and structural biology services supporting drug discovery programs, covering protein expression and purification, membrane proteins, antibodies and biotherapeutics, X-ray crystallography, cryo-EM, macromolecular NMR, and protein characterization including mass spectrometry and FIDA. Its customer base comprised biotech and pharmaceutical sponsors requiring high-quality protein reagents and structural insight for hit identification, hit-to-lead, and lead optimization work.

Peak Proteins no longer operates as an independent entity. It has been fully integrated with Sygnature Discovery, together with NuChem Sciences and SB Drug Discovery, under the unified Sygnature Discovery Limited brand. The combined organization operates from the UK (Nottingham) and Canada (Montréal) and employs over 700 scientists delivering integrated drug discovery from target identification through lead optimization, complemented by scientific solutions in computer-aided drug design, protein and structure sciences, bioscience, chemistry, DMPK, in vivo pharmacology, and form and formulation across multiple modalities and therapeutic areas.

As a contract research organization, the business model is fee-for-service based on custom drug discovery programs and integrated engagements. Pricing is not publicly disclosed and customer concentration data is not available. The combined entity claims to have contributed to multiple clinical candidates and FDA-approved therapies, with founder Dr Simon Hirst leading Sygnature Discovery as CEO.

Peak Proteins firmographics

Firmographics
Name
Peak Proteins
Legal name
Sygnature Discovery Limited
Website
https://peakproteins.com
Company type
Private
Founded year
2010
Operating status
Acquired
Headcount range
11–50 employees
Short description
Peak Proteins was a UK-based contract research organization founded in 2015 by ex-AstraZeneca scientists, providing protein science and structural biology services to drug discovery clients. It has since fully integrated with Sygnature Discovery, NuChem Sciences, and SB Drug Discovery under a single brand.
Ownership category
akta.pro rank

Peak Proteins industry classification

Industry
Product category
Contract Research Organization (Drug Discovery & Protein Science Services)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Protein expression services
  • Structural biology CRO
  • Drug discovery services
  • X-ray crystallography
  • Cryo-EM analysis

Where Peak Proteins is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Markets served

Peak Proteins business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Peak Proteins product offering

Product offering

Core offering

Peak Proteins provides protein science and structural biology research services to pharmaceutical and biotechnology clients, including protein expression and purification, membrane protein production, antibody and biotherapeutic engineering, X-ray crystallography, cryo-EM, macromolecular NMR, protein mass spectrometry, and FIDA-based biophysical characterization. Now fully integrated into Sygnature Discovery, these capabilities are delivered alongside integrated drug discovery programs spanning target identification, hit identification, hit-to-lead, and lead optimization.

Product overview

Peak Proteins operates as part of Sygnature Discovery, a unified contract research organization (CRO) providing integrated drug discovery services. The integrated offering combines multiple service pillars—including Integrated Drug Discovery programs, Computer Aided Drug Design, Protein & Structure sciences, Bioscience, Chemistry, Drug Metabolism and Pharmacokinetics (DMPK), in vivo Pharmacology, and Form & Formulation—delivered by 700+ scientists across Europe and North America. Peak Proteins, along with NuChem Sciences and SB Drug Discovery, has been fully unified under the Sygnature Discovery brand, offering end-to-end drug discovery solutions without competing internal programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Target Identification and Validation Service delivering robust target identification and validation using an integrated AI-enabled and lab-validated platform, intended for pharmaceutical and biotechnology discovery teams needing early-stage target de-risking.
  • Hit Identification Service that delivers validated, high-quality hits via integrated technologies and expert collaboration, for pharmaceutical and biotechnology discovery teams progressing targets into hit-to-lead workflows.
  • Hit-to-Lead Service that progresses high-quality hits through de-risking and profiling with early proof-of-concept work, intended for pharmaceutical and biotechnology discovery teams transitioning toward lead optimisation.
  • Lead Optimization Service that converts promising leads into clinical candidates using medicinal chemistry, structural biology, and DMPK expertise, for pharmaceutical and biotechnology discovery teams advancing toward IND-enabling studies.
  • Protein Expression and Purification Service producing and purifying recombinant proteins for structural biology, biochemistry, and biotherapeutic discovery, intended for pharmaceutical and biotechnology research teams needing protein reagents.
  • Membrane Protein Services Service that produces and characterises membrane proteins to enable structure-based drug design against challenging integral membrane targets, intended for pharmaceutical and biotechnology discovery teams.
  • Antibodies and Biotherapeutics Service engineering and characterising antibodies and biotherapeutic proteins for therapeutic development, intended for pharmaceutical and biotechnology teams developing biologic drugs.
  • X-Ray Crystallography Service providing atomic-resolution X-ray crystal structures of proteins and protein-ligand complexes to support structure-based drug design, intended for pharmaceutical and biotechnology discovery teams.
  • Single-Particle Cryo-EM Service providing high-resolution cryo-electron microscopy structures of proteins and complexes unsuitable for crystallography, intended for pharmaceutical and biotechnology discovery teams working on challenging targets.
  • Macromolecular NMR Service delivering solution-state NMR structural and dynamic characterisation of proteins and ligands, intended for pharmaceutical and biotechnology discovery teams requiring complementary structural insights.
  • Protein Characterization Service providing biophysical and analytical characterisation of proteins, including protein mass spectrometry and FIDA-based analysis, for pharmaceutical and biotechnology teams assessing developability and binding.
  • Bioscience Services Service portfolio covering cell line generation, assay development, electrophysiology, high-throughput screening, and cell-based, biochemical, and biophysical assays, intended for pharmaceutical and biotechnology discovery teams.
  • Computer Aided Drug Design (CADD) Service providing computer-aided drug design spanning bioinformatics, virtual screening, structure-based and ligand-based design, library design, ADMET predictions, and informatics, intended for pharmaceutical and biotechnology discovery teams.

Companies that use Peak Proteins

Customer profile

Ideal customer profiles1 record

Peak Proteins technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Peak Proteins partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sygnature DiscoverycoreStrategic or Co-development PartnerPeak Proteins has fully integrated with Sygnature Discovery, along with NuChem Sciences and SB Drug Discovery, under the unified Sygnature Discovery brand. This integration brings together connected drug discovery capabilities across Europe and North America.

Recent moves5 records

Expansion highlights5 records

Peak Proteins competitors and assessment

Company assessment

Direct peers

  • Domainex: UK-based CRO providing integrated drug discovery services including protein expression, structural biology, medicinal chemistry and DMPK. Highly comparable as a similarly sized UK-headquartered discovery CRO.
  • Sygnature Discovery: Sygnature Discovery is the parent CRO into which Peak Proteins has been fully integrated, offering the same drug discovery, protein science and structural biology services. It is the most directly comparable entity given full operational overlap.
  • SARomics Biostructures: Specialist structural biology CRO offering protein production, crystallography and structure-based drug design. Comparable as a similarly sized, focused structural biology service provider.
  • Proteros: Germany-based specialist in protein science and structure-based drug design, including X-ray crystallography and biophysics. Comparable because it serves the same protein science and structure-based discovery niche from a similar size.

Broad incumbents

  • Eurofins Scientific: Global testing and laboratory services group with significant pharmaceutical and biopharma services exposure. Comparable as a broad incumbent offering protein and analytical services to the biopharma industry.
  • Evotec: Large global drug discovery CRO offering integrated services from target identification through to clinical candidates. Comparable as a broader incumbent in the same integrated discovery services category.
  • WuXi AppTec: Large global CRO/CDMO offering discovery, development and manufacturing services including protein sciences. Comparable as a broad incumbent competing for the same biopharma R&D outsourcing spend.
  • Charles River Laboratories: Major global CRO with extensive drug discovery and early development services. Comparable as an incumbent offering overlapping protein science, structural biology and integrated discovery capabilities, though at much larger scale.

Emerging players

  • XtalPi: AI- and physics-driven drug discovery platform combining computation with structural biology and protein engineering. Comparable as an emerging player intersecting structural biology, protein science and AI-enabled drug design.
  • Crelux (WuXi AppTec): Specialist protein science and structural biology CRO now part of WuXi AppTec, focused on protein production, crystallography and biophysics. Comparable as a focused protein science service provider integrated into a broader CRO.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Peak Proteins social profiles

Digital presence

Peak Proteins financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Peak Proteins leadership team

Management profile

Number of profiles

Peak Proteins subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Peak Proteins funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Peak Proteins M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peak Proteins

What does Peak Proteins do?

Peak Proteins provides protein science and structural biology research services to pharmaceutical and biotechnology clients, including protein expression and purification, membrane protein production, antibody and biotherapeutic engineering, X-ray crystallography, cryo-EM, macromolecular NMR, protein mass spectrometry, and FIDA-based biophysical characterization. Now fully integrated into Sygnature Discovery, these capabilities are delivered alongside integrated drug discovery programs spanning target identification, hit identification, hit-to-lead, and lead optimization.

Is Peak Proteins a public or private company?

Peak Proteins is a private company. It is classified as corporate owned and is currently acquired.

When was Peak Proteins founded?

Peak Proteins was founded in 2010. It employs 11 to 50 people.

Where is Peak Proteins based?

Peak Proteins is headquartered in Macclesfield, United Kingdom, in the Europe region.

Who are Peak Proteins's main competitors?

Direct peers on record are Domainex, Sygnature Discovery, SARomics Biostructures and Proteros. Broad incumbents are Eurofins Scientific, Evotec, WuXi AppTec and Charles River Laboratories. Emerging players are XtalPi and Crelux (WuXi AppTec).

Does Peak Proteins have an API?

No public API is recorded for Peak Proteins.

What industry is Peak Proteins in?

Peak Proteins's product category is Contract Research Organization (Drug Discovery & Protein Science Services). Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalRevolution by Evolution: Protein Science and its Impact on Drug DiscoveryMark Abbott, Managing Director of Peak Proteins, discussed protein science's evolution in drug discovery at SLAS EU 2023. He noted advances in cryo-EM, gene synthesis, and automation, and highlighted AI as a growing impact. He expects faster processes and continued reliance on high-quality protein production.FierceBiotechSygnature Discovery buys Peak Proteins to bolster drug discovery businessPreclinical contractor Sygnature Discovery has acquired Peak Proteins, a chemistry services provider founded by former AstraZeneca scientists, to enhance its drug discovery capabilities. The acquisition brings Peak's 35 staff and its Macclesfield facility into Sygnature's integrated team, expanding its protein production expertise. This move aligns with Sygnature’s growth strategy of adding capabilities through strategic acquisitions.SygnaturediscoverySygnature Discovery acquires Peak ProteinsSygnature Discovery has acquired Peak Proteins Ltd, a protein production and structure determination firm based in Macclesfield, to integrate its capabilities into Sygnature's drug discovery operations. This strategic move expands Sygnature's in-house development scope by combining Peak Proteins' expertise in protein expression and crystallography with Sygnature's existing biophysics and screening services. The transaction marks Sygnature's fourth acquisition in four years and follows a significant equity investment in the company in 2021.